However, studies on patients’ prognosis have shown that an increased expression of CCL18 in tumors such as esophageal squamous cell carcinoma [86], glioma [185], oral squamous cell carcinoma [182], ovarian cancer [55,177], pancreatic cancer [67,185], prostate cancer [185], and urothelial cancer [185] is associated with a worse prognosis. Here, CCL18 is linked to central nervous system cancer.